Related Experiment Video
Updated: Feb 14, 2026

Organotypic Slice Cultures to Study Oligodendrocyte Dynamics and Myelination
Published on: August 25, 2014
Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Hyunjin Ju1,2, Ki Hoon Kim3,4, Sook Young Woo5
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Importance:
The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is still controversial.
Objective:
To investigate the association of late onset MOGAD with moderate disability and relapse in Korean patients.
Design, Setting, And Participants:
This nationwide, multicenter, retrospective cohort study included adult patients with a diagnosis of MOGAD according to the 2023 international diagnostic criteria between August 2018 and September 2024 across 28 hospitals in South Korea.
Exposure:
Age at onset of MOGAD, categorized into adult-onset MOGAD (AO-MOGAD; 18-49 years) and late-onset MOGAD (LO-MOGAD; ≥50 years).
Main Outcomes And Measures:
The primary outcomes were time to first relapse in patients with a disease duration of 12 or more months and moderate disability, defined as Expanded Disability Status Scale (EDSS) score of 3 or greater at last follow-up.
Results:
A total of 350 patients (mean [SD] age at onset, 43.2 [15.0] years; 189 female [54.0%]) with a median (IQR) baseline EDSS of 3.0 (2.0-4.0) were included, with 124 patients (35.4%) with LO-MOGAD and 226 patients (64.6%) with AO-MOGAD. The LO-MOGAD group had less frequent brain involvement than the AO-MOGAD group at onset (26 patients [21.0%] vs 75 patients [33.2%]; P = .02) and during the disease course (28 patients [22.6%] vs 95 patients [42.0%]; P < .001), while optic neuritis or myelitis was comparable between the 2 groups. The LO-MOGAD group showed more frequent monophasic course (55 of 95 patients [57.9%] vs 75 of 188 patients [39.9%]; P = .004), but higher EDSS score at last follow-up (median [IQR], 2.0 [1.0-2.0] vs 1.0 [0.0-2.0]; P < .001) compared with those in the AO-MOGAD group. However, late onset was not significantly associated with the time to first relapse in multivariable analysis (adjusted hazard ratio, 0.72; 95% CI, 0.48-1.08; P = .11), which was consistent after propensity score matching. By contrast, late onset was associated with a significantly higher risk of moderate disability at the last follow-up (adjusted odds ratio, 2.84; 95% CI, 1.39-5.80; P = .004).
Conclusions And Relevance:
In this cohort study of MOGAD, late onset was not associated with a risk of relapse but with a higher risk of moderate disability at follow-up. Prospective studies with longer follow-up periods are warranted to better understand and manage patients with late-onset disease.
Insights
Late onset myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) did not increase relapse risk but was linked to higher moderate disability. Further research is needed for optimal management of late-onset MOGAD.
Area of Science:
- Neurology
- Immunology
- Neuroimmunology
Background:
- The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains controversial.
- Understanding MOGAD onset is crucial for patient management and prognosis.
Purpose of the Study:
- To investigate the association between late onset MOGAD (LO-MOGAD) and moderate disability and relapse in Korean patients.
- To compare outcomes between adult-onset MOGAD (AO-MOGAD) and LO-MOGAD.
Main Methods:
- A nationwide, multicenter, retrospective cohort study included 350 adult MOGAD patients diagnosed using 2023 international criteria.
- Patients were categorized into AO-MOGAD (18-49 years) and LO-MOGAD (≥50 years).
- Primary outcomes included time to first relapse and moderate disability (Expanded Disability Status Scale [EDSS] ≥3).
Main Results:
- Late onset MOGAD (LO-MOGAD) showed less frequent brain involvement but a more frequent monophasic course compared to AO-MOGAD.
- LO-MOGAD was associated with a higher EDSS score at last follow-up.
- Late onset was not significantly associated with relapse risk (aHR, 0.72; P=.11) but was linked to a higher risk of moderate disability (aOR, 2.84; P=.004).
Conclusions:
- Late onset MOGAD is not associated with an increased risk of relapse.
- Late onset MOGAD is associated with a significantly higher risk of moderate disability.
- Prospective studies are warranted to better understand and manage late-onset MOGAD.
More Related Videos
10:47Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
Published on: October 27, 2016
18:17Derivation of Enriched Oligodendrocyte Cultures and Oligodendrocyte/Neuron Myelinating Co-cultures from Post-natal Murine Tissues
Published on: August 21, 2011
Related Concept Videos
Intellectual Disability
Learning Disabilities
Dyslexia
Dyslexia is a...
Matrix Proteoglycans and Glycoproteins
Relative Risk
Nervous Tissue: Myelin
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...